Cognition Therapeutics (CGTX) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Cognition Therapeutics (CGTX) over the past year, losing 37.9% versus a loss of 55.0%. Cognition Therapeutics is the larger company by market cap ($83.4 million vs $74.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGTX | OKYO |
|---|---|---|
| Share price | $0.8769 | $1.42 |
| Market cap | $83.39M | $74.52M |
| 1-day change | -2.04% | +2.16% |
| YTD return | -35.04% | -32.85% |
| 1-year return | -55.03% | -37.95% |
| 5-year return | -92.63% | — |
| EPS (TTM) | $-0.17 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.05 | $3.20 |
| 52-week low | $0.55 | $1.27 |
| Distance from 52-week high | -57.22% | -55.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +279.75% | +486.62% |
| Average volume | 534.62K | 93.79K |
| Shares outstanding | 95.09M | 52.48M |
| Employees | 14 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKYO has outperformed CGTX by 17.1 percentage points over the past year.
About Cognition Therapeutics
CGTX stock →Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
CGTX vs OKYO FAQ
Which is bigger, Cognition Therapeutics or OKYO Pharma?
Cognition Therapeutics (CGTX) is larger, with a market capitalization of $83.39M compared with $74.52M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, CGTX or OKYO?
OKYO returned -37.95% over the past 12 months, compared with -55.03% for CGTX (price return, excluding dividends). Past performance does not predict future results.
Are Cognition Therapeutics and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.